El 18 de agosto del 2021, Sick Cells fue anfitrión de una discusión de mesa redonda con individuos de la comunidad Hispana quienes viven con la enfermedad de células falciformes (ECF) o quienes cuidan por familiares con ECF. El enfoque de la discusión era de identificar brechas educativas claves, crear herramientas educativas dirigidas para llenar estas brechas, e informar nuestras recomendaciones para los grupos interesados. Este reporte es un resumen de nuestros hallazgos.
On August 18th, 2021, Sick Cells hosted a multi-stakeholder roundtable discussion with individuals from the Hispanic community who live with SCD or care for loved ones with SCD. The goal of the roundtable was to understand SCD within the Hispanic community, identify key educational gaps, and create targeted educational tools to fill those gaps. This report is a summary of our findings.
Sick Cells and Avalere Health partnered to host a multi-stakeholder dialogue to discuss and identify barriers to accessing quality care. Through this dialogue, we have developed a strategic roadmap to advance the care and lives of people living with sickle cell.
Since 2019, Sick Cells has worked to highlight the patient voice in coverage decision meetings by training advocates to share their story. To date, Sick Cells has trained over 25 individuals to advocate for sickle cell disease coverage in their state. This paper outlines the process Sick Cells follows to ensure the patient voice is reflected and prioritized in Medicaid coverage decisions across the country, and reviews current barriers and potential solutions to improve stakeholder engagement at these Drug Utilization Review Board (DURB) and Pharmacy & Therapeutics (P&T) committee meetings.
Sick Cells hosted a first-of-its-kind multi-stakeholder summit to discuss the changing landscape of healthcare coverage for sickle cell disease (SCD), called The Coverage for SCD Summit. This report contains proceedings and recommendations from this summit, which are intended to inform next steps to drive collaborative efforts and address gaps in access and coverage for SCD treatments.
